NeoGenomics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial statements are unaudited. NeoGenomics provides oncology diagnostic testing and related services through its Clinical Services and Advanced Diagnostics segments.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $156.2 million | $137.2 million | +13.9% |
| Clinical Services revenue | $134.5 million | $114.9 million | +17.1% |
| Advanced Diagnostics revenue | $21.7 million | $22.4 million | -2.9% |
| Gross profit / margin | $65.5 million / 41.9% | $54.8 million / 39.9% | Margin +2.0 percentage points |
| Operating loss | $30.6 million | $35.1 million | Loss narrowed |
| Net loss | $27.1 million | $30.8 million | Loss narrowed |
| Basic and diluted loss per share | $0.21 | $0.25 | Loss per share narrowed |
| Operating cash flow | -$25.9 million | -$12.7 million | Cash use increased |
Clinical Services growth reflected higher testing volume, a more favorable test mix, and higher average unit prices from reimbursement initiatives. Advanced Diagnostics revenue declined amid pharmaceutical clinical-trial market trends and prioritization of projects expected to be profitable over the longer term. Gross margin improved despite higher compensation, supplies, technology fees, and depreciation costs.
Adjusted EBITDA, a non-GAAP measure, was $3.5 million versus a loss of $7.1 million in Q1 2023. The company reported $5.9 million of Q1 2024 adjustments for other significant expenses, including site closure costs and fees related to non-recurring legal matters; its non-GAAP measure should not be viewed as a substitute for GAAP results or as a liquidity measure.
Liquidity, cash flow, and debt
At March 31, 2024, cash and cash equivalents were $331.9 million and marketable securities were $52.9 million. Working capital was $497.2 million. Cash declined by $10.6 million during the quarter. Operating cash use was $25.9 million, while investing activities provided $14.5 million, primarily from maturities of marketable securities; financing activities provided $0.8 million.
Property and equipment purchases were $5.6 million in the quarter. Management expects 2024 capital expenditures of $35 million to $40 million and believes cash, marketable securities, and collections will fund near-term operating and capital needs for at least 12 months.
Convertible senior notes had a net carrying value of $538.9 million. The notes comprise $201.3 million principal due in 2025 at 1.25% and $345.0 million principal due in 2028 at 0.25%. The 2025 notes mature May 1, 2025; holders could not convert either series during Q2 2024 under the disclosed conversion conditions.
Changes, outlook, and notable items
- Revenue grew 13.9% year over year, led by Clinical Services; Advanced Diagnostics contracted modestly.
- Operating expenses were $96.0 million, including $2.4 million in restructuring charges, down from $4.7 million a year earlier. The company expects approximately $3.8 million in additional 2024 restructuring charges and expects the program to conclude by December 31, 2024.
- Management expects research and development spending to increase as it invests in innovation and new tests. It also expects higher sales commissions in coming quarters. No specific revenue or earnings guidance is provided in the filing text.
- On April 29, 2024, after quarter-end, the FDA announced a final rule changing regulation of laboratory-developed tests. NeoGenomics said it was assessing potential operational effects.
- In the Natera patent litigation, a preliminary injunction issued in December 2023 restricts RaDaR use, with exceptions for certain existing patients and ongoing or approved research and clinical trials. NeoGenomics appealed; oral arguments occurred March 29, 2024, and no decision had been issued at filing. The North Carolina trial is scheduled for March 2025. Related Delaware cases were stayed pending resolution of the North Carolina litigation.
- An ongoing government inquiry concerns certain consulting and service agreements and healthcare-law compliance. The company recorded an $11.2 million reserve, described as its best estimate of the minimum probable loss, but cannot estimate possible losses above that amount. The DOJ is participating in the investigation.
- Other disclosed risks include shareholder securities and derivative lawsuits, reimbursement and regulatory changes, and seasonality. Management reported disclosure controls were effective at a reasonable assurance level and no material internal-control changes occurred during the quarter.
Important facts for investors to verify
- Whether Clinical Services growth and margin improvement continue, and whether Advanced Diagnostics stabilizes.
- Cash conversion and working-capital trends, given the quarter’s increased operating cash use despite a narrower net loss.
- 2025 convertible-note repayment, refinancing, or other liquidity plans ahead of maturity.
- Developments and financial exposure in the RaDaR patent cases and the OIG/DOJ inquiry, including whether reserves change.
- The operational and compliance impact of the FDA’s LDT rule and the company’s planned $35–$40 million of 2024 capital expenditures.